Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case–control study
Authors:
- E ElautEEE Elaut
- E DeclercqEDE Declercq
- G HeylensGHG Heylens
- G De CuypereGCG De Cuypere
- Y TaesYTY Taes
- J M KaufmanJKJ M Kaufman
- G T'SjoenGTG T'Sjoen
- 1 October 2013
- journal article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 169 (4) , 471-478
Abstract
Objective: This study evaluated the short- and long-term cardiovascular- and cancer-related morbidities during cross-sex hormone therapy in a large sample of trans persons.Subjects and methods: A specialist center cross-sectional study compared 214 trans women (male-to-female transsexual persons) and 138 trans men (female-to-male trans persons) with an age- and gender-matched control population (1–3 matching). The participants were on cross-sex hormone therapy for an average of 7.4 years. We assessed physical health and possible treatment-related adverse events using questionnaires.Results: Five percent of trans women experienced venous thrombosis and/or pulmonary embolism during hormone therapy. Five of these adverse events occurred during the first year of treatment, while another three occurred during sex reassignment surgery. Trans women experienced more myocardial infarctions than the control women (P=0.001), but a similar proportion compared with control men. The prevalence of cerebrovascular disease (CVD) was higher in trans women than in the control men (P=0.03). The rates of myocardial infarction and CVD in trans men were similar to the control male and female subjects. The prevalence of type 2 diabetes was higher in both trans men and women than in their respective controls, whereas the rates of cancer were similar compared with the control men and women.Conclusion: Morbidity rate during cross-sex hormone therapy was relatively low, especially in trans men. We observed a higher prevalence of venous thrombosis, myocardial infarction, CVD, and type 2 diabetes in trans women than in the control population. Morbidity rates in trans men and controls were similar, with the exception of the increased prevalence of type 2 diabetes.Keywords
This publication has 32 references indexed in Scilit:
- Long-Term Evaluation of Cross-Sex Hormone Treatment in Transsexual PersonsThe Journal of Sexual Medicine, 2012
- Thrombotic Stroke and Myocardial Infarction with Hormonal ContraceptionNew England Journal of Medicine, 2012
- A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormonesEuropean Journal of Endocrinology, 2011
- Long-Term Follow-Up of Transsexual Persons Undergoing Sex Reassignment Surgery: Cohort Study in SwedenPLOS ONE, 2011
- Safety of Physiological Testosterone Therapy in Women: Lessons from Female-to-Male Transsexuals (FMT) Treated with Pharmacological Testosterone TherapyThe Journal of Sexual Medicine, 2010
- Endocrine Treatment of Transsexual Persons:An Endocrine Society Clinical Practice GuidelineThe Journal of Clinical Endocrinology & Metabolism, 2009
- Long-Term Treatment of Transsexuals with Cross-Sex Hormones: Extensive Personal ExperienceThe Journal of Clinical Endocrinology & Metabolism, 2008
- Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism riskThe Lancet, 2003
- Mortality and morbidity in transsexual subjects treated with cross‐sex hormonesClinical Endocrinology, 1997
- Mortality and morbidity in transsexual patients with cross-gender hormone treatmentMetabolism, 1989